在疟疾流行非洲地区创新性使用羟基脲(NOHARM):针对镰状细胞贫血儿童的试验
NOHARM是在疟疾流行乌干达开展的随机双盲安慰剂对照试验,比较羟基脲20±2.5 mg/kg/日与安慰剂治疗镰状细胞贫血儿童12个月。羟基脲组与安慰剂组疟疾发病率无差异,镰状细胞贫血相关复合临床结局羟基脲组45%低于安慰剂组69%(P=.001),严重不良事件、脓毒症发作和剂量限制性毒性相似。
要点
- 羟基脲组疟疾发病率0.05次/儿童年 vs 安慰剂组0.07次/儿童年,发病率比0.7(95%CI 0.2-2.7;P=.61)。
- 镰状细胞贫血相关复合临床结局羟基脲组45% vs 安慰剂组69%(P=.001)。
- 羟基脲组血红蛋白和胎儿血红蛋白显著升高,白细胞和网织红细胞降低。
核心结论
- 羟基脲治疗对生活在疟疾流行撒哈拉以南非洲的镰状细胞贫血儿童似乎安全,未增加严重疟疾、感染或不良事件。
- 羟基脲提供镰状细胞贫血相关的实验室和临床疗效,但非洲的最佳剂量和监测方案仍未确定。
研究设计与样本
- NOHARM(在疟疾流行非洲地区创新性使用羟基脲)是在疟疾流行乌干达开展的随机双盲安慰剂对照试验。
- 比较羟基脲20±2.5 mg/kg/日与安慰剂治疗12个月。
- 主要结局为临床疟疾发病率;次要结局包括镰状细胞贫血相关不良事件、临床和实验室效应及血液学毒性。
- 儿童接受羟基脲(N=104)或安慰剂(N=103)。
- 试验注册号NCT01976416。
主要发现
- 羟基脲组疟疾发病率为0.05次/儿童年(95%CI 0.02-0.13) vs 安慰剂组0.07次/儿童年(95%CI 0.03-0.16);羟基脲/安慰剂疟疾发病率比为0.7(95%CI 0.2-2.7;P=.61)。
- 至感染时间在治疗组间也无显著差异。
- 镰状细胞贫血相关复合临床结局(血管闭塞性疼痛危象、指趾炎、急性胸部综合征、脾隔离症或输血)羟基脲组45% vs 安慰剂组69%(P=.001)。
- 接受羟基脲的儿童血红蛋白浓度和胎儿血红蛋白显著升高,白细胞和网织红细胞降低。
- 严重不良事件、脓毒症发作和剂量限制性毒性在治疗组间相似;发生3例死亡(羟基脲组2例,安慰剂组1例,无疟疾所致死亡)。
临床怎么用
- 原文结论指出羟基脲治疗对生活在疟疾流行撒哈拉以南非洲的镰状细胞贫血儿童似乎安全,未增加严重疟疾、感染或不良事件。
- 原文结论指出羟基脲提供镰状细胞贫血相关的实验室和临床疗效,但非洲的最佳剂量和监测方案仍未确定。
局限性
- 非洲的最佳剂量和监测方案仍未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hydroxyurea treatment is recommended for children with sickle cell anemia (SCA) living in high-resource malaria-free regions, but its safety and efficacy in malaria-endemic sub-Saharan Africa, where the greatest sickle-cell burden exists, remain unknown. In vitro studies suggest hydroxyurea could increase malaria severity, and hydroxyurea-associated neutropenia could worsen infections. NOHARM (Novel use Of Hydroxyurea in an African Region with Malaria) was a randomized, double-blinded, placebo-controlled trial conducted in malaria-endemic Uganda, comparing hydroxyurea to placebo at 20 ± 2.5 mg/kg per day for 12 months. The primary outcome was incidence of clinical malaria. Secondary outcomes included SCA-related adverse events (AEs), clinical and laboratory effects, and hematological toxicities. Children received either hydroxyurea (N = 104) or placebo (N = 103). Malaria incidence did not differ between children on hydroxyurea (0.05 episodes per child per year; 95% confidence interval [0.02, 0.13]) vs placebo (0.07 episodes per child per year [0.03, 0.16]); the hydroxyurea/placebo malaria incidence rate ratio was 0.7 ([0.2, 2.7]; P = .61). Time to infection also did not differ significantly between treatment arms. A composite SCA-related clinical outcome (vaso-occlusive painful crisis, dactylitis, acute chest syndrome, splenic sequestration, or blood transfusion) was less frequent with hydroxyurea (45%) than placebo (69%; P = .001). Children receiving hydroxyurea had significantly increased hemoglobin concentration and fetal hemoglobin, with decreased leukocytes and reticulocytes. Serious AEs, sepsis episodes, and dose-limiting toxicities were similar between treatment arms. Three deaths occurred (2 hydroxyurea, 1 placebo, and none from malaria). Hydroxyurea treatment appears safe for children with SCA living in malaria-endemic sub-Saharan Africa, without increased severe malaria, infections, or AEs. Hydroxyurea provides SCA-related laboratory and clinical efficacy, but optimal dosing and monitoring regimens for Africa remain undefined. This trial was registered at www.clinicaltrials.gov as #NCT01976416.
引用
- Opoka RO, Ndugwa CM, Latham TS, et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017. PMID: 29051184. doi:10.1182/blood-2017-06-788935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。